KR20240133723A - Fab 단편의 분무화 - Google Patents

Fab 단편의 분무화 Download PDF

Info

Publication number
KR20240133723A
KR20240133723A KR1020247024543A KR20247024543A KR20240133723A KR 20240133723 A KR20240133723 A KR 20240133723A KR 1020247024543 A KR1020247024543 A KR 1020247024543A KR 20247024543 A KR20247024543 A KR 20247024543A KR 20240133723 A KR20240133723 A KR 20240133723A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
less
domain
fab fragment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024543A
Other languages
English (en)
Korean (ko)
Inventor
나탈리 헤즈-부크
폴 세바스찬 반 데르 워닝
장-미셸 페르시어
Original Assignee
아르제넥스 비브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아르제넥스 비브이 filed Critical 아르제넥스 비브이
Publication of KR20240133723A publication Critical patent/KR20240133723A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247024543A 2022-01-18 2023-01-18 Fab 단편의 분무화 Pending KR20240133723A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202200592 2022-01-18
GB2200592.0 2022-01-18
PCT/EP2023/051073 WO2023139090A1 (en) 2022-01-18 2023-01-18 Nebulization of fab fragments

Publications (1)

Publication Number Publication Date
KR20240133723A true KR20240133723A (ko) 2024-09-04

Family

ID=85036924

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024543A Pending KR20240133723A (ko) 2022-01-18 2023-01-18 Fab 단편의 분무화

Country Status (10)

Country Link
US (1) US20250059284A1 (https=)
EP (1) EP4466009A1 (https=)
JP (1) JP2025503701A (https=)
KR (1) KR20240133723A (https=)
CN (1) CN118434440A (https=)
AU (1) AU2023210422A1 (https=)
CA (1) CA3236113A1 (https=)
IL (1) IL314365A (https=)
MX (1) MX2024007659A (https=)
WO (1) WO2023139090A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Also Published As

Publication number Publication date
US20250059284A1 (en) 2025-02-20
WO2023139090A1 (en) 2023-07-27
CA3236113A1 (en) 2023-07-27
IL314365A (en) 2024-09-01
JP2025503701A (ja) 2025-02-04
AU2023210422A1 (en) 2024-05-23
MX2024007659A (es) 2024-07-04
EP4466009A1 (en) 2024-11-27
CN118434440A (zh) 2024-08-02

Similar Documents

Publication Publication Date Title
JP7079844B2 (ja) 高濃度抗ｃ５抗体製剤
US20240294628A1 (en) Biopharmaceutical compositions
RU2731644C2 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
TWI761869B (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
US20250099386A1 (en) Dry Powder Formulations of Thymic Stromal Lymphopoietin (TSLP)-Binding Antibodies and Methods of Use Thereof
EA038332B1 (ru) Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
JP7843248B2 (ja) ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法
US20220144937A1 (en) Pharmaceutical composition containing antibody against il-5 and use thereof
US20250059284A1 (en) Nebulization of fab fragments
HK40107259A (zh) Fab片段的雾化
EA050653B1 (ru) НЕБУЛИЗАЦИЯ Fab-ФРАГМЕНТОВ
TW202529811A (zh) 胸腺基質淋巴細胞生成素（ｔｓｌｐ）結合片段之組成物及其使用方法
CN114341183B (zh) Il20-rb特异性抗体及其用于治疗慢性阻塞性肺疾病急性恶化的用途
HK40096185A (zh) 生物医药组合物
WO2026086834A1 (zh) 抗ox40抗体在治疗皮炎疾病中的用途
JP2025515781A (ja) フォラルマブの経鼻製剤
HK40060532A (en) Formulations containing anti-cd47/pd-l1 bispecific antibody and preparation method therefor and use thereof
HK40059623B (zh) 包含抗il-5抗体的药物组合物及其用途
HK40080447A (en) Biopharmaceutical compositions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000